REGENERON PHARMACEUTICALS, INC.: financing cash flow

What this measure means

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Exact concept: us-gaap:NetCashProvidedByUsedInFinancingActivities. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2008-01-01 to 2025-12-31. The SEC response was captured on 2026-09-19.

Selected filing history

Related financial histories

• REGENERON PHARMACEUTICALS, INC.: total assets
• REGENERON PHARMACEUTICALS, INC.: total liabilities
• REGENERON PHARMACEUTICALS, INC.: stockholders equity
• REGENERON PHARMACEUTICALS, INC.: cash and cash equivalents
• REGENERON PHARMACEUTICALS, INC.: net income or loss
• REGENERON PHARMACEUTICALS, INC.: operating cash flow
• REGENERON PHARMACEUTICALS, INC.: revenue
• REGENERON PHARMACEUTICALS, INC.: contract revenue excluding tax
• REGENERON PHARMACEUTICALS, INC.: investing cash flow
• REGENERON PHARMACEUTICALS, INC.: retained earnings or deficit
• REGENERON PHARMACEUTICALS, INC.: basic weighted-average shares
• REGENERON PHARMACEUTICALS, INC.: diluted weighted-average shares
• REGENERON PHARMACEUTICALS, INC.: basic earnings per share
• REGENERON PHARMACEUTICALS, INC.: diluted earnings per share
• REGENERON PHARMACEUTICALS, INC.: income tax expense or benefit
• REGENERON PHARMACEUTICALS, INC.: net property, plant and equipment
• REGENERON PHARMACEUTICALS, INC.: share-based compensation expense
• REGENERON PHARMACEUTICALS, INC.: operating income or loss
• REGENERON PHARMACEUTICALS, INC.: current assets
• REGENERON PHARMACEUTICALS, INC.: interest expense
• REGENERON PHARMACEUTICALS, INC.: current liabilities
• REGENERON PHARMACEUTICALS, INC.: current accounts payable
• REGENERON PHARMACEUTICALS, INC.: net current accounts receivable
• REGENERON PHARMACEUTICALS, INC.: common-stock repurchase payments
• REGENERON PHARMACEUTICALS, INC.: net inventory
• REGENERON PHARMACEUTICALS, INC.: selling, general and administrative expense
• REGENERON PHARMACEUTICALS, INC.: research and development expense

Inspect the source

Entity

REGENERON PHARMACEUTICALS, INC. / CIK 0000872589

Captured

2026-09-19T11:15:01.411Z

SEC response SHA-256

8ac8537cd8b5e571e7f527aae3e223c6a7cdab1260fd8035e278ac184b4901b4

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000872589.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))